

## TO THE EDITOR:

## *KMT2A-CBL* rearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Alex Bataller,<sup>1,2,\*</sup> Francesca Guijarro,<sup>3,\*</sup> Aurélie Caye-Eude,<sup>4</sup> Marion Strullu,<sup>5</sup> Arthur Sterin,<sup>6</sup> Oscar Molina,<sup>2</sup> Patrice Chevallier,<sup>7</sup> Marketa Zaliova,<sup>8</sup> Jan Zuna,<sup>8</sup> Pablo Mozas,<sup>1</sup> Laura Magnano,<sup>1</sup> Nathalie Gardel,<sup>9</sup> Pascale Cornillet-Lefebvre,<sup>10</sup> Jen-Fen Fu,<sup>11</sup> Lee-Yung Shih,<sup>12</sup> Temenuzka Boneva,<sup>13</sup> Elisabeth Nacheva,<sup>13</sup> Silvia Beà,<sup>3,14</sup> Mònica López-Guerra,<sup>3,14</sup> Clara Bueno,<sup>2,14,15</sup> Pablo Menéndez,<sup>2,14-16</sup> Jordi Esteve,<sup>1,2</sup> Patrizia Larghero,<sup>17</sup> Claus Meyer,<sup>17</sup> and Rolf Marschalek<sup>17</sup>

<sup>1</sup>Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); <sup>2</sup>Josep Carreras Leukemia Research Institute, School of Medicine, <sup>3</sup>Hematopathology Section, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; <sup>4</sup>Department of Genetics and Molecular Genetics; <sup>5</sup>Department of Pediatric Hematology, AP-HP, Robert Debré Hospital, Paris, France; <sup>6</sup>Department of Pediatric Hematology, Immunology and Oncology, APHM, La Timone Children Hospital, Marseille, France; <sup>7</sup>Hematology Department, CHU Hotel-Dieu, Nantes, France; <sup>8</sup>CLIP, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University Prague and University Hospital Motol, Prague, Czech Republic; <sup>9</sup>Department of Hematology, University Hospital Claude Huriez, Lille, France; <sup>10</sup>Laboratoire d'Hématologie, Hôpital Robert Debré, Reims, France; <sup>11</sup>Department of Medical Research, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan; <sup>12</sup>Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan; <sup>13</sup>HSL Analytics LLP OncoGenomics, London, United Kingdom and UCL Cancer Institute, UK; <sup>14</sup>Centro de Investigación Biomédica en Red de Cáncer, <sup>15</sup>RICORS-TERAV, ISCIII, Madrid, Spain; <sup>16</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; and <sup>17</sup>Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University, Frankfurt/Main, Germany

*KMT2A* (*MLL*) abnormalities are common in leukemias of various lineages. Specifically, *KMT2A* chromosomal rearrangements are present in about 5% to 15% of all adolescents and young adults diagnosed with acute lymphoblastic leukemia (ALL) and in 3% of all adult patients with acute myeloid leukemia (AML).<sup>1,2</sup> Thus far, more than 100 *KMT2A* partner genes have been described, *AFF1* (*AF4*) and *MLLT3* (*AF9*) being the most common ones, mainly associated with ALL and AML, respectively.<sup>3</sup> Although the *KMT2A* recombinome has been largely studied in B-cell ALL (B-ALL), its characterization in T-cell ALL (T-ALL) is still limited, with *KMT2A* rearrangements accounting for about 2% to 5% of all T-ALL cases.<sup>4</sup> In T-ALL, in turn, the most frequent partner genes involved in *KMT2A* rearrangements are *MLLT1* (*ENL*) and *AFDN* (*AF6*).<sup>3,4</sup>

*CBL* (also known as *c-CBL*, casitas B-lineage leukemia) encodes for a ubiquitin-ligase (E3s) involved in the negative regulation of signaling mediated by multiple tyrosine kinase receptors. This protein is a member of the Cbl family of proto-oncogenes, which has 3 members (*CBL*, *CBLB*, and *CBLC*) and is ubiquitously expressed in the cytoplasm of many tissues.<sup>5</sup> The protein domain structure of Cbl is presented in Figure 1A. At its N-terminal portion, there is a tyrosine kinase-binding (TKB) domain, an EF hand, and a Src homology 2 domain (SH2). Its main function is to bind multiple cytoplasmatic substrates, including tyrosine kinase proteins. The zinc-binding Really Interesting New Gene (RING) finger domain, which regulates the E3 ubiquitin ligase activity of c-Cbl, brings in an E2 ubiquitin-conjugating enzyme and therefore ubiquitylates the substrate bound to the TKB domain. Adjacent to the RING domain, there is a proline-rich region involved in protein/protein interactions via inducible association with SH2 and SH3. At the C-terminal portion, there is a ubiquitin associated/leucine zipper domain (UBA/LZ), crucial for Cbl homodimerization.


Several mutations in *CBL* have been described in various hematologic disorders, mostly in myeloid malignancies. The frequency of *CBL* mutations has been as high as 15% and 4% of adult myelodysplastic/myeloproliferative diseases and myeloproliferative neoplasms, respectively. In AML, its frequency is lower: approximately 1% to 2%.<sup>6</sup> In juvenile myelomonocytic leukemia (JMML), *CBL* mutations are also common, with a frequency of 17%.<sup>7</sup> In ALL, although rare, a few reports have described *CBL* mutations in both T- and B-cell lineages, especially in *KMT2A*-rearranged leukemias.<sup>8,9</sup> *CBL* mutations consist mostly of point mutations clustering in exons 8 and 9, involving the linker and RING domain<sup>6</sup> (Figure 1A). The proposed oncogenic mechanism of *CBL* mutations is

Submitted 12 July 2021; accepted 13 September 2021; prepublished online on *Blood Advances* First Edition 12 October 2021; final version published online 28 December 2021. DOI 10.1182/bloodadvances.2021005736.

\*A.B. and F.G. contributed equally to this study.

Requests for data sharing may be submitted to Alex Bataller (abataller@clinic.cat).

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.



**Figure 1. CBL structure and *KMT2A-CBL* rearrangements.** (A) Structure of the CBL protein and its domains: 4-helix bundle (4H), EF-hand-calcium binding (EF), SRC homology 2 (SH2), RING finger (RF), proline-rich domain (PR), and ubiquitin-associated domain (UBA). Phosphorylation sites (P) and predicted protein breakpoints for each patient are also represented. (B) Schematic representation of *KMT2A* and *CBL* genes with the breakpoint for each patient.

based on intracellular signaling deregulation because of the loss of CBL inhibitory function.<sup>10</sup> Interestingly, in *CBL*-mutated myeloid neoplasms, a loss of the germline *CBL* allele has been demonstrated, mostly because of uniparental disomy.<sup>11</sup>

To our knowledge, only 4 reports of hematologic neoplasms harboring a *KMT2A-CBL* gene fusion (3 of them under the diagnosis of AML) have been published.<sup>3,12,13</sup> International collaborative efforts, such as the *MLL* recombinome database, are crucial to identify and collect these rare rearrangements. Along with the previously published cases, we have now identified 3 new cases with the same rearrangement but in distinct hematologic malignancies (Table 1). It has been described that *KMT2A* breakpoints mostly localize within exon 9 and intron 11, with an association of intron 9 breakpoints with AML or older patients and intron 11 with ALL and younger patients.<sup>3</sup> In our cohort, all patients had their breakpoint within the previous described limits, 4 of them clustering in intron 9, although establishing associations between age or diagnosis with this finding seems far-fetched. *CBL* breakpoints also cluster in intron 9 (Figure 1). The *KMT2A-CBL* fusions of patients 2 and 7 are per se out of frame. However, the reverse transcriptase-polymerase chain reaction (RT-PCR) of case 2 revealed a cryptic exon composed of the truncated exon 10 of *KMT2A* and additional filler DNA that

maintains the reading frame. This mechanism could also explain the *KMT2A-CBL* rearrangement of patient 7, but this hypothesis could not be verified because of the lack of material. This study has been approved by the Ethics Committee of Hospital Clínic de Barcelona. Code:HCB/2021/0010 and was conducted in accordance with the Declaration of Helsinki.

Despite the limited number of patients, some biological insights about this rare rearrangement can be extracted from our findings. We report for the first time that *KMT2A-CBL* rearrangements are present not only in AML and B-ALL but also in T-ALL. Moreover, 2 of these cases were secondary neoplasms (JMML and polycythemia vera; both received prior chemotherapeutic agents), which is also common in *KMT2A*-rearranged leukemias. *CBL* is located in chromosome 11q23, at a distance of 680 kb from *KMT2A*, suggesting that *KMT2A-CBL* rearrangements are necessarily caused either by an interstitial deletion or by a translocation event occurring between both homologous chromosomes 11. Split-signal FISH analysis can reveal these types of rearrangements, whereas conventional cytogenetics usually fails to detect them. Subsequently, different diagnostic techniques can be used to identify *CBL* as the *KMT2A* fusion partner, although their implementation in the clinical routine might be difficult. Targeted next-generation sequencing (NGS) is a feasible

**Table 1. Patients with KMT2A-CBL rearrangement**

	Patient 1 (Marseille)	Patient 2 (Reims)	Patient 3 (Barcelona)	Patient 4 <sup>3</sup> (Prague)	Patient 5 <sup>2</sup> (Taiwan)	Patient 6 <sup>3</sup> (Nantes)	Patient 7 <sup>13</sup> (London)
Sex, age (y)	Male, 9	Male, 11	Male, 18	Male, 3	Female, 28	Female, 59	Female, 18
Medical history	JMML - KRAS mut 6MP & CB-AlloSCT (Bu/Cy)	None	None	Development delay	None	Polycythemia vera JAK2+ Hydroxyurea and pipobroman	None
Hematologic diagnosis	T-ALL (EGIL T2)	T-ALL (EGIL T2)	T-ALL (EGIL T2)	B-ALL (EGIL B1)	AML (FAB M1)	sAML (FAB M5)	AML
White blood count ( $\times 10^9$ /L)	1.1	5.39	12.32	65.5	0.8	37.5	1.3
Hemoglobin (g/L)	90	97	83	107	44	107	74
Platelets ( $\times 10^9$ /L)	109	69	24	71	15	45	55
Blast count peripheral blood/bone marrow (%)	0/97	33/99	85/99	80/93	47/96	65/83	
Flow cytometry	cCD3 <sup>+</sup> , sCD3 <sup>-</sup> , TdT <sup>+</sup> , CD99 <sup>+</sup> , CD7 <sup>+</sup> , CD2 <sup>+</sup> , CD5 <sup>+</sup> , CD34 <sup>-</sup> dim, CD38 <sup>+</sup> , CD13 <sup>+</sup> , CD38 <sup>+</sup>	cCD3 <sup>+</sup> , sCD3 <sup>+</sup> dim, CD2 <sup>+</sup> , CD5 <sup>+</sup> , TdT <sup>+</sup> , CD99 <sup>+</sup> dim, CD1a <sup>+</sup> , CD7 <sup>+</sup> , CD38 <sup>+</sup>	cCD3 <sup>+</sup> , sCD3 <sup>+</sup> dim, CD34 <sup>-</sup> , TdT <sup>+</sup> , CD19 <sup>+</sup> , CD79a <sup>+</sup> , CD10 <sup>+</sup> , CD7 <sup>+</sup> dim, CD38 <sup>+</sup>	CD34 <sup>-</sup> , TdT <sup>+</sup> , CD19 <sup>+</sup> , CD33 <sup>+</sup>	CD34 <sup>-</sup> , CD13 <sup>+</sup> , CD33 <sup>+</sup> , CD38 <sup>+</sup> , CD4 <sup>+</sup>	CD34 <sup>+</sup> , cMPO <sup>+</sup> , CD33 <sup>+</sup> , CD15 <sup>+</sup> , CD38 <sup>+</sup> , CD56 <sup>+</sup>	
Cytogenetics	Pseudodiploid and monosomic with 3 clonal anomalies: del(2q), -16,r	47,XY,?del(5)(q31),+8, del(9)(q13;q34),del(11)(q21;q23), del(12)(p11)(cp6)/46,XY[28]	47,XY,der(7),+19[20]	NA	50,XX,+22,+3 mar [5]/49,XX,-19,+22,+3mar [11]/46,XX,inv(9)[4]	45~46,XX,-5,add(6)(p21),-9,+i(9)(p10), add(11)(q23),-18,+mar[7], 47~49,XX,+2,-5,-9,i(9q10),add(11)(q23), ?+13,-18,+19,+20,inc[9]	46,XX[20]
KMT2A FISH	KMT2A 3' loss of signal	KMT2A 3' loss of signal	KMT2A 3' loss of signal	KMT2A 3' loss of signal	-	KMT2A 3' loss of signal	KMT2A 3' loss of signal
NGS	KRAS p.G13C (VAF 32%) ASXL1 p.G646Wfs12 (VAF 26%) STAT3 p.N481I (VAF 36%)	IL7R p.V253_A254insVA (VAF 13%) KMT2A p.N*2278fs (VAF 82%) NOTCH1 p.P2514fs (VAF 16%) NOTCH1 p.A1700D (VAF 10%) NOTCH1 p.L1678P (VAF 36%) ZFH4 p.R2676Q (VAF 28%)	No mutations detected	KRAS p.A18D (VAF 44%)	CBL p.L380P (VAF 70%)		RUNX1 p.G372S (VAF 50%)
Method for KMT2A-CBL detection	RNAseq and targeted NGS	RNAseq and Targeted NGS	Targeted NGS	RNAseq and LDI-PCR	cdNA panhandle PCR Validated by RT-PCR + cloning and sequencing of the KMT2A fusion product.	RNAseq and LDI-PCR	Chromosomal microarray analysis
Breakpoint	KMT2A intron 9 CBL intron 9	KMT2A exon 10 CBL intron 15	KMT2A intron 9 CBL intron 9	KMT2A intron 10 CBL intron 9	KMT2A intron 9 CBL intron 9	KMT2A intron 9 CBL intron 9	KMT2A intron 10 CBL exon 2
Clinical outcome	Induction Chemotherapy (CALL-T protocol) - CR MRD+ Consolidation + Intensification - CR MRD-CB-AlloSCT Alive, CR 1 y after diagnosis	Induction chemotherapy (CAALL-F01 protocol) NR Consolidation + Intensification - CR MRD- RD-AlloSCT Alive, CR 3 y after diagnosis	Induction chemotherapy (PETHEMA 2019) - PR Re-induction (FLAG-IDA) - CR MRD- IntReALL SR 2010 protocol CR-MRD+ Blinatumomab x 2 MUD-AlloSCT Alive, CR 13 y after diagnosis	Induction chemotherapy CR Relapse after 8 y Relapse 2 y after diagnosis Reinduction MUD-AlloSCT Deceased due to alloSCT complications	Induction chemotherapy CR Consolidation - CR Relapse 2 y after diagnosis Reinduction MUD-AlloSCT Deceased due to alloSCT complications	Induction chemotherapy CR Consolidation CR RD-AlloSCT Relapse 11 mo after diagnosis Azacytidine: No response Deceased because of disease progression	Induction chemotherapy CR Loss of follow-up

In cytogenetic studies, number of metaphases studied is represented in brackets.

6MP, mercaptopurine; AlloSCT, allogeneic stem cell transplantation; CB, cord blood; CR, complete response; EGIL, European Group for the Immunological Classification of Leukemia; FAB, French-American-British classification; LDI-PCR, long-distance-inverse PCR; MRD, minimal residual disease; MUD, matched unrelated donor; NR, no response; PR, partial response; RD, related donor; VAF, variant allele frequency.

alternative to detect this and other rare rearrangements included in the panel.

In terms of the leukemogenic effect of *KMT2A-CBL* rearrangements, to date, there are no specific models that can clearly explain its mechanism. CBL is a cytoplasmatic protein so its effect in the leukemic cell might be different from that of nuclear factors like *AFF1* or *MLLT3*.<sup>14</sup> In fact, it has been hypothesized that rearrangements of *KMT2A* with cytoplasmatic proteins could trigger their oncogenic effects through dimerization of the chimeric *KMT2A* protein, enhancing a specific gene expression program.<sup>15</sup> This is supported by the retention of the UBA domain responsible for the homodimerization of CBL in all the *KMT2A-CBL* cases reported in the present study. Thus, dimerization of *KMT2A-CBL* through the UBA domains could be an important leukemogenic mechanism to be explored. Another alternative explanation is that the translocated protein domains might exert novel functions in the wrong cellular compartments. In addition, the resulting truncated CBL protein most likely represents a genetic “loss-of-function” situation, as already observed in hematological neoplasms with *CBL* inactivating mutations.<sup>10</sup>

To conclude, *KMT2A-CBL* rearrangements are rare events identified in leukemias of various lineages. Conventional cytogenetics may miss such rearrangements but the increasingly widespread use of targeted sequencing techniques in the diagnostic work-up will probably increase the number of cases identified. International collaborative efforts are necessary to improve the characterization of the *KMT2A-CBL* rearrangement and investigate its prognostic impact. Ultimately, functional experiments of *KMT2A-CBL* gain-of-function models and CD34<sup>+</sup> hematopoietic progenitor cells may provide fundamental knowledge about the leukemogenic potential and the cell-of-origin of *KMT2A-CBL* leukemias.

**Acknowledgments:** The authors thank Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for institutional support.

**Contribution:** A.B., F.G., M.S., A.S., O.M., P.C., M.Z., J.Z., P.M., L.M., N.G., P.C.-L., J.-F.F., L.-Y.S., T.B., E.N., S.B., and M.L.-G. provided clinical and biological information of all cases; A.C.-E., C.B., P.M., P.L., C.M., and R.M. provided genetic data; and A.B. and F.G. collected the data and wrote the manuscript along with C.B., P.M., J.E., P.L., C.M., and R.M. All authors reviewed the final manuscript.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**ORCID profiles:** A.B., 0000-0002-6085-2745; F.G., 0000-0001-6376-0929; O.M., 0000-0001-7585-4519; M.Z., 0000-0002-1639-7124; P.M., 0000-0001-9528-4971; N.G., 0000-0001-6573-1312; L.-Y.S., 0000-0003-1866-7922; S.B., 0000-0001-7192-2385; R.M., 0000-0003-4870-3445.

**Correspondence:** Alex Bataller, Department of Hematology, Hospital Clínic de Barcelona, Carrer Villarroel 170, 08036 Barcelona,

Spain; email: abataler@clinic.cat and Francesca Guijarro, Hematopathology Section, Hospital Clínic de Barcelona, Carrer Villarroel 170, 08036 Barcelona, Spain; email: fguijarro@clinic.cat.

## References

1. Malard F, Mohty M. Acute lymphoblastic leukaemia. *Lancet*. 2020; 395(10230):1146-1162.
2. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
3. Meyer C, Burmeister T, Gröger D, et al. The MLL recombinome of acute leukemias in 2017. *Leukemia*. 2018;32(2):273-284.
4. Türkmen S, Timmermann B, Bartels G, et al. Involvement of the MLL gene in adult T-lymphoblastic leukemia. *Genes Chromosom Cancer*. 2012;51(12):1114-1124.
5. Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. *J Leukoc Biol*. 2002;71(5):753-763.
6. Schnittger S, Bacher U, Alpermann T, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. *Haematologica*. 2012;97(12):1890-1894.
7. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. *Blood*. 2009; 114(9):1859-1863.
8. Saito Y, Aoki Y, Muramatsu H, et al. Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. *Leuk Res*. 2012;36(8):1009-1015.
9. Shiba N, Park MJ, Taki T, et al. CBL mutations in infant acute lymphoblastic leukaemia. *Br J Haematol*. 2012;156(5): 672-674.
10. Katzav S, Schmitz ML. Mutations of c-Cbl in myeloid malignancies. *Oncotarget*. 2015;6(13):10689-10696.
11. Sanada M, Suzuki T, Shih L-Y, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. *Nature*. 2009; 460(7257):904-908.
12. Fu JF, Hsu JJ, Tang TC, Shih LY. Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia. *Genes Chromosom Cancer*. 2003;37(2):214-219.
13. Boneva T, Nacheva E. *KMT2A-CBL* fusion gene resulting from del(11)(q23.3q23.3) identified by chromosome microarray analysis-second report in AML. *Atlas Genet Cytogenet Oncol Haematol*. 2020;24(6):262-264.
14. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. *Nat Rev Cancer*. 2007;7(11):823-833.
15. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. *Cancer Cell*. 2003;4(2):99-110.